logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kim Linton

University of Manchester
H指数:34
被引数:5,530

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial

avelumab抗PD-L1抗体在复发/难治性PTCL中的IIa期研究：AVAIL-T试验

British Journal of Haematology
IF3.8
2026-09-200
OAAI
Matthew J. Ahearne; Matthew A. Timmins; Charlotte Gaskell; Aimee Jackson; Clare Morland; Sonia Fox; Louise Hopkins; Nadia Nawaz; Susann Lehmann; Marc Wadsley; Caroline Cowley; Jacqueline Shaw; Naeem Khan; Nagesh Kalakonda; Christopher Trethewey; Ram Malladi; Paul Fields; Dima El Sharkawi; Michael Quinn; Nimish Shah; Andrew Davies; Kim Linton; Pam McKay; Rod Johnson; Simon D. Wagner; David Lewis; Graham P. Collins; Christopher P. Fox; Kate Cwynarski
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL

通过PBMCs和ctDNA评估的微小残留病阴性证实了epcoritamab单药治疗在复发/难治性滤泡性淋巴瘤中的深度和持久缓解

Blood Advances
IF7.1
2026-07-140
OA
Işıl Altıntaş; Christopher Morehouse; Elena Favaro; Ali Rana; John Karavitis; Edith Szafer-Glusman; Kevin Zhao; Kim Linton; Alexey Danilov; Ann S. LaCasce; Lorenzo Falchi; Jessica Okosun; Tahamtan Ahmadi; Mark Fereshteh; Maria Jure-Kunkel; David Soong; Andrew J. Steele
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Epcoritamab、lenalidomide和rituximab与lenalidomide和rituximab治疗复发或难治性滤泡性淋巴瘤的比较（EPCORE FL-1）：一项全球性、开放标签、随机、III期临床试验

The Lancet
IF97.3
2025-12-070
OAAI
Lorenzo Falchi; Marcel Nijland; Huiqiang Huang; Kim M Linton; John F Seymour; Rong Tao; Michal Kwiatek; Abel Costa; Theodoros P Vassilakopoulos; Richard Greil; Ana Jiménez-Ubieto; Shane A Gangatharan; Ohad Benjamini; Catherine Thieblemont; Alessandra Tucci; Anna Elinder-Camburn; Arpad Illes; Jan Novak; Miguel A Pavlovsky; Andrew McDonald
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

固定疗程的Epcoritamab联合R2方案可改善复发或难治性滤泡性淋巴瘤患者的预后。

Blood
IF23.1
2025-09-100
OAAI
Lorenzo Falchi; Anna Sureda; Sirpa Leppä; Joost S.P. Vermaat; Marcel Nijland; Jacob Haaber Christensen; Sven de Vos; Harald Holte; Reid W. Merryman; Pieternella J. Lugtenburg; Pau Abrisqueta; Kim M. Linton; Gauri Sunkersett; Daniela Hoehn; Ali Rana; Aqeel Abbas; Jennifer Marek; Yi Hao; Andrew J. Steele; Christopher Morehouse; Martin Hutchings; David Belada
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

与化疗免疫疗法、mosunetuzumab 或 odronextamab 在滤泡性淋巴瘤中的 epcoritamab 间接比较

Blood Advances
IF7.1
2025-06-090
OA
Alexey V. Danilov; Swetha Kambhampati Thiruvengadam; Kim Linton; Karen Cumings; Viktor Chirikov; Alex Mutebi; Savreet Bains Chawla; Anindit Chhibber; Fernando Rivas Navarro; Felipe Marques Gonçalves; Anthony Wang; Zhijie Ding; Abualbishr Alshreef; Elena Favaro; Daniela Hoehn; Anna Sureda
Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Glofitamab和Epcoritamab在真实世界中的疗效、耐受性及实际意义：一项英国多中心回顾性分析

BLOOD
IF23.1
2024-11-051
PRE
Haynes, Euan; Ediriwickrema, Kushani; Lawless, Sarah; Joyce, Kevin; Wells, Matthew; Smith, Jeffrey; Linton, Kim; Santarsieri, Anna; Follows, George; Willan, John; Osborn, Robert; Wilson, Matthew; Mckay, Pamela; Baloch, Mahina; Mcculloch, Rory; Gleeson, Mary; Wrench, David; Foldes, David; Kanfer, Edward; Maw, Kyaw Zin; Kuhnl, Andrea; Ahearne, Matthew; Owen, Mary; Norman, Jane; De Silva, Ravindu; Shah, Nimish; Ambrose, Harriet; Fox, Christopher P.; Qasim, Janine; Collins, Graham P.; Vickers, Martha; Tucker, David; Chan, Li Yuan; Lyengar, Sunil; el-Sharkawi, Dima; Auer, Rebecca; Cox, Catherine; Hiew, Hwai Jing; Davies, Andrew J.; Kelsey, Philippa; Lewis, David John; Martin, Abigail; Preston, Gavin; Culligan, Dominic J.; Broom, Angus; Wilson, William; Osborne, Wendy; Townsend, William
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Epcoritamab治疗复发/难治性大b细胞淋巴瘤: 关键的EPCORE NHL-1试验的2年随访

LEUKEMIA
IF13.4
2024-09-250
OAAI
Thieblemont, Catherine; Karimi, Yasmin H.; Ghesquieres, Herve; Cheah, Chan Y.; Clausen, Michael Roost; Cunningham, David; Jurczak, Wojciech; Do, Young Rok; Gasiorowski, Robin; Lewis, David John; Kim, Tae Min; van der Poel, Marjolein; Poon, Michelle Limei; Feldman, Tatyana; Linton, Kim M.; Sureda, Anna; Hutchings, Martin; Dinh, Minh H.; Kilavuz, Nurgul; Soong, David; Mark, Thomas; Sacchi, Mariana; Phillips, Tycel; Lugtenburg, Pieternella J.
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

PI3Kδ 抑制剂zandelisib间歇给药治疗复发/难治性滤泡性淋巴瘤: 一项全球2期研究的结果

HEMASPHERE
IF14.6
2024-08-060
OAAI
Zelenetz, Andrew D.; Jurczak, Wojciech; Ribrag, Vincent; Linton, Kim; Collins, Graham P.; Jimenez, Javier L.; Bishton, Mark; Dholaria, Bhagirathbhai; Mengarelli, Andrea; Phillips, Tycel J.; Sungala, Nagendraprasad; Musuraca, Gerardo; Sheehy, Oonagh; Van Den Neste, Eric; Odera, Mitsuhiko; Miao, Lu; Gold, Daniel P.; Ghalie, Richard G.; Zinzani, Pier L.
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Epcoritamab单药治疗复发性或难治性滤泡性淋巴瘤患者 (EPCORE NHL-1): 单臂多中心研究的2期队列

LANCET HAEMATOLOGY
IF17.7
2024-08-018
PRE
Linton, Kim M.; Vitolo, Umberto; Jurczak, Wojciech; Lugtenburg, Pieternella J.; Gyan, Emmanuel; Sureda, Anna; Christensen, Jacob Haaber; Hess, Brian; Tilly, Herve; Cordoba, Raul; Lewis, David John; Okada, Craig; Hutchings, Martin; Clausen, Michael Roost; Sancho, Juan-Manuel; Cochrane, Tara; Leppa, Sirpa; Chamuleau, Martine E. D.; Gernhardt, Diana; Altintas, Isil; Liu, Yan; Ahmadi, Tahamtan; Dinh, Minh H.; Hoehn, Daniela; Favaro, Elena; Elliott, Brian; Thieblemont, Catherine; Vose, Julie M.
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial
BMC CANCER
IF3.4
2024-03-250
OAAI
Mcilroy, Graham; Lax, Sian; Gaskell, Charlotte; Jackson, Aimee; Rhodes, Malcolm; Seale, Tania; Fox, Sonia; Hopkins, Lousie; Okosun, Jessica; Barrington, Sally F.; Ringshausen, Ingo; Ramsay, Alan G.; Calaminici, Maria; Linton, Kim; Bishton, Mark
Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Soong, David; Altintas, Isil; Karavitis, John; Linton, Kim M.; Jurczak, Wojciech; Thieblemont, Catherine; Zhao, Kevin; Szafer-Glusman, Edith; Hoehn, Daniela; Favaro, Elena; Sacchi, Mariana; Jure-Kunkel, Maria
Ibrutinib as fi rst-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
BLOOD ADVANCES
IF7.1
2024-03-014
OAAI
Tivey, Ann; Shotton, Rohan; Eyre, Toby A.; Lewis, David; Stanton, Louise; Allchin, Rebecca; Walter, Harriet; Miall, Fiona; Zhao, Rui; Santarsieri, Anna; Mcculloch, Rory; Bishton, Mark; Beech, Amy; Willimott, Victoria; Fowler, Nicole; Bedford, Claudia; Goddard, Jack; Protheroe, Sam; Everden, Angharad; Tucker, David; Wright, Josh; Dukka, Vasavi; Reeve, Miriam; Paneesha, Shankara; Prahladan, Mahesh; Hodson, Andrew; Qureshi, Iman; Koppana, Manasvi; Owen, Mary; Ediriwickrema, Kushani; Marr, Helen; Wilson, Jamie; Lambert, Jonathan; Wrench, David; Burney, Claire; Knott, Chloe; Talbot, Georgina; Gibb, Adam; Lord, Angela; Jackson, Barry; Stern, Simon; Sutton, Taylor; Webb, Amy; Wilson, Marketa; Thomas, Nicky; Norman, Jane; Davies, Elizabeth; Lowry, Lisa; Maddox, Jamie; Phillips, Neil; Crosbie, Nicola; Flont, Marcin; Nga, Emma; Virchis, Andres; Camacho, Raisa Guerrero; Swe, Wunna; Pillai, Arvind; Rees, Clare; Bailey, James; Jones, Steve; Smith, Susan; Sharpley, Faye; Hildyard, Catherine; Mohamedbhai, Sajir; Nicholson, Toby; Moule, Simon; Chaturvedi, Anshuman; Linton, Kim
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
BLOOD ADVANCES
IF7.1
2024-02-153
OAAI
Shotton, Rohan; Broadbent, Rachel; Alchawaf, Alia; Mohamed, Mohamed Bakri; Gibb, Adam; Martinez-Calle, Nicolas; Fox, Christopher P.; Bishton, Mark; Pender, Alexandra; Gleeson, Mary; Cunningham, David; Davies, Andrew; Yadollahi, Sina; Eyre, Toby A.; Collins, Graham; Djebbari, Faouzi; Kassam, Shireen; Garland, Paula; Watts, Emily; Osborne, Wendy; Townsend, William; Pocock, Rachael; Aheame, Matthew J.; Mial, Fiona; Wang, Xin; Linton, Kim M.
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
BLOOD ADVANCES
IF7.1
2023-11-1510
OAAI
Opat, Stephen; Tedeschi, Alessandra; Hu, Bei; Linton, Kim M.; Mckay, Pamela; Leitch, Sophie; Coleman, Morton; Zinzani, Pier Luigi; Jin, Jie; Sun, Mingyuan; Sobieraj-Teague, Magdalena; Browett, Peter; Ke, Xiaoyan; Thieblemont, Catherine; Ardeshna, Kirit; Bijou, Fontanet; Walker, Patricia; Hawkes, Eliza A.; Ho, Shir-Jing; Zhou, Keshu; Liang, Zhiyu; Xu, Jianfeng; Tankersley, Chris; Delarue, Richard; Co, Melannie; Trotman, Judith

研究方向

暂未获取到该数据
J
John Radford
H 指数:87论文数:693被引数:2.9万
C
Christopher P. Fox
H 指数:46论文数:334被引数:8,319
K
Kate Cwynarski
H 指数:51论文数:262被引数:8,401
G
Graham P. Collins
H 指数:39论文数:398被引数:9,413
D
David Lewis
H 指数:23论文数:114被引数:3,108
D
David Cunningham
H 指数:153论文数:2,060被引数:13.0万
T
Toby A. Eyre
H 指数:39论文数:386被引数:5,753
M
Mark Bishton
H 指数:26论文数:162被引数:2,324
A
Andrew Davies
H 指数:72论文数:667被引数:2.2万
C
Catherine Thiéblemont
H 指数:100论文数:886被引数:3.5万